Abstract
Aims
Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have proven valuable for studies in drug discovery and safety, although limitations regarding their structural and electrophysiological characteristics persist. In this study, we investigated the electrophysiological properties of Pluricyte® CMs, a commercially available hiPSC-CMs line with a ventricular phenotype, and assessed arrhythmia incidence by IKr block at the single-cell and 2D monolayer level.
Methods and results
Action potentials were measured at different pacing frequencies, using dynamic clamp. Through voltage-clamp experiments, we determined the properties of INa, IKr, and ICaL. Intracellular Ca2+ measurements included Ca2+-transients at baseline and during caffeine perfusion. Effects of IKr block were assessed in single hiPSC-CMs and 2D monolayers (multi-electrode arrays). Action-potential duration (APD) and its rate dependence in Pluricyte® CMs were comparable to those reported for native human CMs. INa, IKr, and ICaL revealed amplitudes, kinetics, and voltage dependence of activation/inactivation similar to other hiPSC-CM lines and, to some extent, to native CMs. Near-physiological Ca2+-induced Ca2+ release, response to caffeine and excitation–contraction coupling gain characterized the cellular Ca2+-handling. Dofetilide prolonged the APD and field-potential duration, and induced early afterdepolarizations. Beat-to-beat variability of repolarization duration increased significantly before the first arrhythmic events in single Pluricyte® CMs and 2D monolayers, and predicted pending arrhythmias better than action-potential prolongation.
Conclusion
Taking their ion-current characteristics and Ca2+ handling into account, Pluricyte® CMs are suitable for in vitro studies on action potentials and field potentials. Beat-to-beat variability of repolarization duration proved useful to evaluate the dynamics of repolarization instability and demonstrated its significance as proarrhythmic marker in hiPSC-CMs during IKr block.
Keywords: Human-induced pluripotent stem cell-derived cardiomyocytes, Ion channel, Calcium handling, Beat-to-beat variability of repolarization, Arrhythmia inducibility, Multi-electrode arrays
What’s new?
We took a multilevel approach (patch clamp and multi-electrode array) to examine electrophysiological characteristics and the effects of IKr block in a commercially available human-induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) line with a ventricular-like phenotype.
For the first time in single hiPSC-CMs and 2D monolayers, the temporal changes in beat-to-beat variability of repolarization duration were assessed.
Beat-to-beat variability of repolarization duration was superior to action-potential prolongation per se in predicting arrhythmic events during IKr block.
Introduction
Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have created new perspectives in many fields, including developmental biology, drug testing, safety pharmacology, and disease modelling.1 The implementation of cellular models for in vitro safety pharmacology has reduced drug attrition due to proarrhythmic effects.2 Concurrently, the approval rate of new drugs fell,3 indicating the need for more specific proarrhythmic tests and biomarkers. In this context, a public–private collaboration, the CiPA (Comprehensive In vitro Proarrhythmia Assay) initiative, proposed the use of hiPSC-CMs to detect missed or unanticipated electrophysiological responses to medicinal compounds and assess proarrhythmic risk.4
Although protocols for reprogramming, differentiation and maturation of hiPSC-CMs have improved over the last decade, structural and electrophysiological limitations hinder their wide-spread application. hiPSC-CMs have a poorly developed T-tubular system, so that Ca2+ handling only partially resembles that of human adult native cardiomyocytes.5 Furthermore, the maximum diastolic potential of hiPSC-CMs is generally less hyperpolarized than that of adult myocytes, which could be explained by a higher expression of HCN4 channels and a smaller inward-rectifier K+ current (IK1).6 Nonetheless, the use of hiPSC-CMs is growing, and various groups and companies have developed cell lines with more mature phenotypes, which are potentially suitable for drug screening.
In the present study, we investigated the electrophysiological and Ca2+-handling properties of one such hiPSC-CMs cell line, commercially available as Pluricyte® Cardiomyocytes (Pluricyte® CMs). The injection of a simulated virtual IK1 through the dynamic-clamp technique (DC) allowed us to restore a physiological resting membrane potential, and to determine the rate dependence of the evoked action potentials (APs). Furthermore, we showed that the biophysical properties of crucial currents that characterize these APs (i.e. INa, ICaL, IKr) and Ca2+-handling properties are similar to other sources of hiPSC-CMs and, in some cases, comparable to native CMs. We determined the potential value of hiPSC-CMs for proarrhythmic risk assessment using repolarization prolongation, beat-to-beat variability of repolarization duration (BVR), and arrhythmia incidence as indicators. We demonstrate that, along with repolarization prolongation, BVR increases after application of the IKr blocker dofetilide, both in single hiPSC-CMs and 2D monolayers. We also showed, for the first time in hiPSC-CMs, that an excessive increase in BVR precedes the first arrhythmic events during IKr block and therefore predicts the occurrence of arrhythmic events better than AP-prolongation per se.
Methods
Cell culture
hiPSC-CMs (Pluricyte® CMs) were provided by Ncardia (Gosselies, Belgium) as cryopreserved samples, and stored in liquid nitrogen until thawed. Thawing and culturing were carried out according to the manufacturer’s protocols. Once thawed, Pluricyte® CMs were maintained in an incubator (37°C, 5% CO2), in Pluricyte® Cardiomyocyte Medium (Ncardia). Medium was refreshed at day 1 post-thaw and subsequently every other day. For manual patch clamp, the cells were seeded on 6-mm glass coverslips (VWR, Radnor, USA) coated with Matrigel (Corning Inc., New York, USA, Ref. 354277) and placed into 35-mm dishes (Greiner Bio-One, GmbH, Solingen, Germany), with a density of 300 000–400 000 cells/dish. For patch clamp, Pluricyte® CMs were tested 5–7 days after thawing. A single coverslip was placed in the recording chamber of an inverted microscope and used for about 1 h of recordings. For multi-electrode arrays (MEA), cells were seeded onto 48-well MEA plates (Axion Biosystems, Inc., Atlanta, USA) coated with fibronectin (50 µg/mL in PBS with Ca2+ and Mg2+, Sigma-Aldrich, Cat. No. F-1141), with a density of 30 000 cells/well. Multi-electrode array recordings were performed at day 8 post-thaw.
Single-cell measurements (patch clamp)
Patch-clamp experiments were performed using an inverted microscope (Nikon Inc., Tokyo, Japan), with an Axon 200B amplifier (Molecular Devices, LLC, San Jose, USA) and an Axon Digidata 1322a digitizer (Molecular Devices, LLC, San Jose, USA). Data were acquired using pCLAMP8 (Molecular Devices, LLC, San Jose, USA) and analysed with Clampfit 10.7 (Molecular Devices, LLC, San Jose, USA). Extracellular and pipette solutions for each condition are summarized in the Supplementary material online, Table S1, in which the protocols used in voltage-clamp experiments are also shown (Supplementary material online, Figure S1).
I Na recordings were performed at room temperature (22 ± 1°C). Currents were sampled at 20 kHz after low-pass filtering at 10 kHz. The protocol repetition rate was 0.2 Hz. The holding potential was set to −70 mV and a 200 ms-conditioning step at −120 mV assured complete recruitment of Na+ channels (Supplementary material online, Figure S1A). This protocol allowed the simultaneous recording of steady-state activation (in the increasing voltage steps of 500 ms) and inactivation in the final step at −20 mV for 25 ms. For steady-state activation, the voltage dependence of normalized Na+ conductance [g/gmax; with g calculated as I/(V − Erev), where I is the peak INa during a depolarizing step, V is the command potential, and Erev is the reversal potential of INa] was fitted with a Boltzmann equation [g/gmax = 1/[1 − exp (V − V1/2)/k]] to determine the membrane potential for half-maximal activation (V1/2) and the slope factor (k). The same equation was applied to determine V1/2 and k for steady-state inactivation using I/maximal I (Imax) at the −20 mV final step. The intersection of the steady-state voltage-dependent activation and inactivation (‘window current’) was analysed to deduct the voltage range, the ‘crossing point’ and the maximum amplitude reached at that point in voltage (in arbitrary units). The time course of inactivation was fitted using a double exponential function [I(t)=A1*exp(-t/τ1)+A2*exp (-t/τ2)], where A is amplitude and τ time constant. Borosilicate glass pipettes (Science Products GmbH, Germany) were pulled (DMZ Universal Electrode Puller, Zeitz-Instruments, GmbH Martinsried, Germany) at a resistance of 1.5–2.5 MΩ.
I Kr was recorded at 36 ± 1°C as the current sensitive to its selective blocker dofetilide. Five µmol/L nifedipine and 1 µmol/L HMR1556 were added to further rule out interference by ICaL and IKs, respectively. From a holding potential of −40 mV, voltage steps (from −60 to +50 mV) of 1 s were applied (protocols repetition rate was 0.3 Hz, Supplementary material online, Figure S1). IKr amplitude was measured as the peak tail current upon repolarizing to the holding potential. The activation curve was obtained from the tail IKrI/V relationship fitted with the Boltzmann function to determine voltage of half-maximal activation (V1/2, mV) and slope factor (k, mV). The ‘rectifier ratio’ was calculated as the ratio between the conductance (G) of the current at the end of the depolarizing steps and the correspondent tail conductance (at −40 mV). The time course of current deactivation was analysed using a single-exponential function, yielding a time constant (τ).
I CaL recordings were performed at room temperature, to minimize current run-down. Currents were sampled at 10 kHz after low-pass filtering at 5 kHz; the protocol's repetition rate was 0.2 Hz. Steady-state activation was assessed in 200 ms-long voltage steps (from −60 to +60 mV), preceded by a 200 ms-step to −40 mV to fully inactivate INa (Supplementary material online, Figure S1). Steady-state inactivation was analysed in the final 300 ms-step at 0 mV, preceded by increasing voltage steps of 2 s from −60 to +5 mV. The holding potential was, in both cases, −70 mV. Steady-state activation and inactivation were fitted using a Boltzmann equation, as reported for INa. Window-current analysis was carried out as for INa. The time course of inactivation was analysed using a mono-exponential function and assessing the time constant (τ). Intracellular Ca2+ was buffered by adding 10 mmol/L ethylene glycol-bis(β-aminoethyl ether)-N, N, N′,N′-tetraacetic acid (EGTA) to the intracellular solution (Supplementary material online, Table S1).
Current clamp: Contracting Pluricyte® CMs were selected for AP recordings at 36 ± 1°C, using the perforated patch-clamp technique (Supplementary material online, Table S1). Pluricyte® CMs were paced to steady-state at frequencies of 0.5, 1, 2 and 3 Hz. No correction of the liquid junction potential was made.
Dynamic clamp: In hiPSC-CMs, DC was used to overcome the lower expression of IK1, by injecting IK1 from a human ventricular numerical model into the patched cells (details in the Supplementary material online, Methods).
Intracellular Ca2+ recordings
Before recordings, Pluricyte® CMs were incubated for 20 min in the membrane-permeable Ca2+-sensitive dye Fluo4-AM (5 µmol/L) and then washed for 5–10 min with Tyrode to eliminate the dye excess. The dye was excited at 480 nm and emission was collected through a 535-nm band-pass filter using a photomultiplier detection system (Photon Technology International, Inc., NJ, USA). Light emission was amplified, converted to voltage, low-pass filtered and digitized at 2 kHz. Background luminescence was recorded from a cell-free field and subtracted. The fluorescence signal of diastolic Ca2+ of the first recorded transient was used as reference fluorescence (F0) for signal normalization (F/F0). Intracellular Ca2+ recordings were performed under voltage-clamp conditions, at 36 ± 1°C.
From a holding potential of −40 mV, depolarizing steps of 200 ms to 0 mV were applied to trigger Ca2+-transients; the total sweep duration was 3 s. To quantify sarcoplasmic-reticulum (SR) Ca2+ content, a caffeine pulse (10 mmol/L) was applied after a loading train of three depolarizing steps and the amplitude of the resulting Ca2+-transient was measured. To analyse the rate of Ca2+-transient relaxation, a standard mono-exponential function was used to fit the decay of the depolarization-induced Ca2+-transient, yielding a time constant τ. The fractional release was calculated as the ratio between the amplitude of depolarization-induced Ca2+-transient and SR Ca2+ content and, for clarity, converted to a percentage. The excitation–contraction coupling (ECC) gain was calculated as the ratio between the amplitude of depolarization-induced Ca2+ transient and peak amplitude of the corresponding ICaL signal7; ECC gain was therefore expressed in arbitrary units (A.U.).
Multi-electrode arrays
At day 8 post-thaw, 2 h after medium refreshment, the 48-well MEA plate seeded with Pluricyte® CMs was placed in the Maestro MEA device (768-channel amplifier) with an integrated heating system, temperature controller and data-acquisition interface (Axion BioSystems, Inc., Atlanta, 94 USA). Baseline recordings were performed after an equilibration period of 10 min. Pluricyte® CMs were cumulatively exposed to four different concentrations of dofetilide (0–10 nmol/L, Tocris-BioTechne, Abingdon, UK) under non-sterile conditions in eight replicates for each concentration. Vehicle control was DMSO (0.000003–0.0003%; n = 6). Final DMSO concentrations matched the dofetilide final concentrations. Recordings of 10 min were performed after 20 min incubation time per concentration. All recording conditions were at 37°C using standard filters and amplifiers in spontaneous cardiac mode (12.5 Hz sampling frequency; 2 kHz Kaiser window; 0.1 Hz IIR). The field-potential detection threshold was set at 300 µV. To determine the effect of dofetilide on the field-potential duration (FPD) with high certainty, data files were analysed using the CiPA Tool software (Axion Biosystems, version 2.0.14). For each well, the FPD was quantified from the electrode with the best trackable repolarization feature (‘golden electrode’). Markers for depolarization peak and repolarization peak were adjusted manually if needed.
Beat-to-beat variability of action-potential and field-potential duration
Action-potential duration (APD)-BVR was quantified as short-term variability of hiPSC-CMs APD at 90% repolarization (APD90), for 30 consecutive APs, at baseline and during dofetilide application, before any early afterdepolarization (EAD) had occurred, using the following formula: ∑|APD90(n-1) − APD90(n)|/(nAPs*√2). In the cells that did not show EADs, we selected the interval at which the effect of the dofetilide was maximal. Repolarization delay per se was not considered an EAD unless the membrane potential showed a clear depolarization before complete repolarization.
FPD-BVR: per condition, 4 min on a total of 10 min MEA recording were exported for BVR analysis in Clampfit 11 using the Axion Data Export Tool (Axion Biosystems, version 3.2.5). Recordings were selected from one electrode per well, four wells per condition. The electrode corresponded to the same electrode used for FPD analysis by the CiPA Tool. The selection of the 30 consecutive beats was made by evaluating the RR interval variability and by selecting the moment with the smallest variation during the 4 min, to rule out any interference. If an arrhythmic event was detected, BVR was calculated in the 30 beats before the very first one. BVR was calculated using the same formula as described for the APD-BVR. In total, BVR at four conditions was analysed: baseline, 0.3 nmol/L, 1 nmol/L, and 3 nmol/L dofetilide.
Statistical analysis
Data are expressed as mean ± standard error of the mean. All statistical tests were conducted using SPSS (IBM, USA), and a P-value < 0.05 was considered significant. For the analysis of the single-hiPSC-CM experiments, a paired- or unpaired T-test was used, with a confidence interval level of 95%. When the data did not satisfy the assumptions of parametric tests (i.e. the samples were not normally distributed, such as the values of BVR in the +EADs group), a non-parametric test was used (related samples Wilcoxon signed-rank test). For MEA data, repeated-measures analysis of variance with a confidence interval adjustment (Bonferroni) was used.
Results
Electrophysiological characterization of Pluricyte® CMs: action-potential features
In Pluricyte® CMs, the average maximum diastolic membrane potential was −47 ± 1.5 mV (n = 23). To reach a value of approximately −85 mV, a modelled, real-time computed IK1-like current was injected.8Figure 1A shows a representative example of the DC approach: starting from a spontaneous series of APs, the injection of the computed IK1 restored the resting membrane potential to −85 mV and conferred the AP a typical adult-like shape. Figure 1B depicts a single AP from a Pluricyte® CM, with the correspondent current injected by DC.
Using DC, we measured the APD90 at different pacing lengths. In Pluricyte® CMs, APD90 adapted to increasing cycle length, as expected (APD90-330ms: 138 ± 18, n = 7; APD90-500ms: 166 ± 23 ms, n = 11; APD90-1000ms: 184 ± 19 ms, n = 16; APD90-2000ms: 193 ± 37 ms, n = 6). The relationship between these two parameters showed a non-linear trend (Figure 1C).
Ion currents and Ca2+ handling in Pluricyte® CMs
Na+ current (INa)
I Na in Pluricyte® CMs (Figure 2A) showed a peak amplitude of −201 ± 20 pA/pF at −21 ± 1 mV (n = 19; Figure 2B). The time course of inactivation was best fitted by a double exponential equation, generating a fast and a slow time constant (τ), as depicted in Figure 2C. At the voltage of maximum INa activation (−20 mV), the slow and fast components reached values of 16 ± 1 ms and 1.8 ± 0.1 ms, respectively (n = 16).
The steady-state activation and inactivation curves were fitted by the Boltzmann equation and the estimated midpoints (V1/2) were −36.9 ± 1.0 and −78.7 ± 1.7 mV, respectively, with k values of 5.3 ± 0.2 and 7.2 ± 0.2 mV (Figure 2D, n = 19). The area under the intersection of the two curves, known as ‘window’ current, spanned voltages between −70 and −30 mV. A small, non-inactivating component was also present. The voltage at which the window current was maximal (5% of maximal conductance) was −57 mV (inset Figure 2D).
Rapidly-activating delayed-rectifier K+ current IKr
A representative example of IKr recorded in Pluricyte® CMs is depicted in Figure 2E. The I–V plot of IKr tail shows a peak of 1.5 ± 0.1 pA/pF at +28 ± 4 mV (n = 18; Figure 2F). When the activation curve was fitted with the Boltzmann equation, the V1/2 was −21 ± 2 mV, with a k of 8.4 ± 0.8 mV (Figure 2G, n = 18). Figure 2H shows the relationship between the depolarizing step and the tail conductance, known as rectifier ratio, for each voltage. The time constant (τ) of tail current deactivation (at −40 mV), estimated by mono-exponential fitting, was 365 ± 19 ms (n = 9).
L-type Ca2+ current (ICaL)
Figure 3A shows a representative ICaL recording in a Pluricyte® CM. During voltage-dependent activation, ICaL reached a peak of −12 ± 1 pA/pF at 0 mV (n = 14; Figure 3B). ICaL inactivation was fitted by a single-exponential equation and at 0 mV (maximum ICaL density) the τ was 51.8 ± 4.5 ms (Figure 3C). The V1/2 of the steady-state activation was −17.1 ± 1.0 mV and a slope factor (k) of 6.7 ± 0.2 mV (n = 10). The steady-state inactivation V1/2 was −38.3 ± 1.2 mV, with a k of 5.8 ± 0.3 mV (Figure 3D, n = 9). Window ICaL (inset of Figure 3D) showed a voltage range between −40 and −15 mV, and achieved 20% of maximal activation at −34 mV.
Ca2+ handling
Cells showed robust depolarization-triggered Ca2+-transients, characterized by a time-to-peak of 194 ± 10 ms and a time constant of decay (τ) of 309 ± 23 ms (Figure 3E; n = 23). The triggering inward membrane current, measured simultaneously with the transients, mainly reflects ICaL., with a peak density of −13.8 ± 1.9 pA/pF (at 0 mV; n = 23), comparable to ICaL recorded at the same potential in the voltage-clamp experiments above. To quantify the efficiency of the coupling between the ICaL and SR Ca2+ release, we calculated the ECC gain. At 0 mV, the ECC gain yielded a value of 0.14 A.U. (n = 8). It should be noted that, because of its arbitrary units, this value should be used only as a qualitative reference for comparisons.
In response to the caffeine pulse, Pluricyte® CMs generated Ca2+-transients with a larger amplitude and longer duration compared to the preceding ICaL-triggered transients (1.66 ± 0.22 vs. 0.87 ± 0.14 A.U., P < 0.001; Figure 3F–G; n = 9). Exponential fitting of the decay of the caffeine-induced transient, which is representative of Na+-Ca2+-exchange-dependent (SERCA-independent) Ca2+ clearance, yielded a time constant of 833 ± 158 ms. This value is much larger than the τ of depolarization-induced Ca2+-transients (312 ± 44 ms; n = 9; P = 0.003; Figure 3G), thus suggesting a significant SERCA contribution to cytosolic Ca2+ clearance during physiological activity, quantified as 57 ± 0.1% (n = 9).
The fraction of total SR Ca2+ content released by the ICaL-triggered Ca2+-transient, known as ‘fractional SR Ca2+ release’, was 51 ± 4.7% (n = 9).
Caffeine elicited a transient inward current (Iti), with a peak current density of −2.5 ± 0.4 pA/pF.
Repolarization effects by IKr block in single human-induced pluripotent stem cell-derived cardiomyocytes
We superfused the cells with dofetilide (100 nmol/L), a specific IKr blocker clinically linked to an increased in vivo risk of torsades de pointes (TdP),4 while pacing them at 1 Hz. We evaluated three parameters: the prolongation of APD90, the degree of BVR [a measure of repolarization (in)stability], and the occurrence of EADs. Figure 4A depicts the shortest and the longest APs (in a series of 30) before and during dofetilide treatment, with the Poincaré plot visualizing the beat-by-beat APD90 dynamics (Figure 4B). On average, the APD90 prolonged from 135 ± 10 ms at baseline to 227 ± 16 ms (in the absence of EADs; Figure 4C; n = 20; P < 0.001). Interestingly, BVR also increased from 2.7 ± 0.3 ms at baseline to 14.2 ± 2.5 ms during dofetilide treatment (Figure 4D; n = 20; P < 0.001). Figure 4E shows a representative example of a cell in which dofetilide caused an EAD. In 20 cells, none showed EADs at baseline, while 10 exhibited EADs during dofetilide and 10 did not (Figure 4F). For further analysis, we divided the dofetilide-treated cells in two groups, according to whether they (eventually) generated EADs (‘+EADs’; n = 10) or not (‘no EAD’; n = 10). Figure 5A depicts a representative example of a cell from the ‘no EAD’ group. Compared to baseline (trace), APD90 and BVR gradually increased (Figure 5B). Likewise, we analysed a cell from the ‘+EADs group’ (Figure 5C). In this case, BVR excessively increased before the first EAD occurred, as shown in Figure 5D.
On average, dofetilide caused a significant APD increase in both groups (no-EAD group: APDbas = 123 ± 13 ms vs. APDdof = 205 ± 23 ms; n = 10; P < 0.001. +EADs group: APDbas = 147 ± 16 ms vs. APDdof = 248 ± 22 ms; n = 10; P < 0.001, Figure 5E). Interestingly, the APD after dofetilide treatment was not significantly different between the two groups (APDdof-noEADs = 205 ± 23 ms vs. APDdof-+EADs = 248 ± 22 ms; n = 10; 10; P = 0.20). The average BVR in the EAD-negative cells was ∼4-fold larger after dofetilide compared to baseline (no-EADs: BVRbas = 2.3 ± 0.4 ms vs. BVRdof = 8.3 ± 1.8 ms; n = 10; P = 0.004), while the +EAD group showed (before the first EAD) almost seven times larger BVR value than at baseline (+EADs: BVRbas = 3.1 ± 0.3 ms vs. BVRdof = 20.0 ± 3.9 ms; n = 10; P = 0.005, Figure 5F). In contrast to what was observed for APD, BVR during dofetilide administration was significantly increased between the two groups, suggesting a better prediction by BVR of pending arrhythmias (BVRdof-no EADs = 8.3 ± 1.8 ms vs. BVRdof-+EADs = 20.0 ± 3.9 ms; n = 10; 10; P = 0.005).
Repolarization effects by IKr block in human-induced pluripotent stem cell-derived cardiomyocytes monolayers
Next, we focused on the response to IKr block in 2D monolayers of Pluricyte® CMs, using MEA technology. Figure 6A shows representative traces of field potentials at baseline and after application of escalating concentrations of dofetilide. The FPD increased progressively, as summarized in Figure 6B. Similarly, as for single Pluricyte® CMs, BVR of FPD was evaluated for each concentration. Figure 6C shows a representative example of the Poincaré plot for a specific electrode at 0.3, 1, and 3 nmol/L dofetilide. The extreme increase in FPD-BVR at the highest concentration preceded the first arrhythmic event, similar to what was found in isolated hiPSC-CMs. On average, BVR showed a concentration-dependent increase, which was highest at 3 nmol/L (110 ± 25 ms; Figure 6D).
At 3 nmol/L, dofetilide caused single abnormal impulses or bursts of arrhythmia in ∼30% of the electrodes (in a total of eight wells analysed), whereas at 10 nmol/L 88% of the electrodes showed arrhythmias and the remaining 12% displayed a quiescent signal (Figure 6E).4 Representative examples are depicted in Figure 6F.
Discussion
In the present study, we determined the action-potential contour, duration and rate dependence of hiPSC-CMs (Pluricyte® CMs), after setting the resting membrane potential to −85 mV. The ion currents investigated, i.e. INa, IKr, ICaL, revealed properties of amplitude, kinetics and voltage dependence similar to other hiPSC-CM lines and, to some extent, to native CMs. Intracellular Ca2+-handling studies showed a functional Ca2+-induced Ca2+-release, a sizable ECC gain, and an adequate response to caffeine. During IKr block by dofetilide, prolongation of APD90 was accompanied by an increased BVR, especially before first EADs occurred. Multi-electrode array experiments on hiPSC-CMs monolayers confirmed this pronounced increase in BVR, actually before the first occurrence of abnormal impulses and bursts of arrhythmia.
The ‘IK1 injection’ achieved by DC enabled us to characterize the AP parameters at a near-physiological resting membrane potential. This is particularly important for the recruitment and functioning of Na+ channels and for ICaL and IKr. Analogous to adult native cells, Pluricyte® CMs showed a typical rate dependence in APD. The use of DC did not decrease the cell-to-cell variability in the APD90, as was already shown in ventricular-like hiPSC-CMs by Verkerk et al.8
The INa in Pluricyte® CMs showed a robust amplitude and a typical steady-state voltage-dependent activation and inactivation at 70 mmol/L extracellular Na+ concentration (used to assure proper voltage control). Our INa data are comparable to results obtained in other hiPSC-CMs cell lines.6 There are only few reports on INa in native human CMs and the comparison is difficult because of different experimental conditions. In the report on hiPSC-CMs by Sakakibara et al.,9 both activation and inactivation mid-points were more hyperpolarized than in our hiPSC-CMs. Window INa was shifted more to the left, with a crossing-point at −70.5 mV, compared to Pluricyte® CMs at −57 mV. The temporal dynamics of INa inactivation in Pluricyte® CMs were comparable to those of non-diseased native human CMs, as reported by Sakakibara et al.,9 being (at −20 mV) τF = 2.1 ± 0.1 ms and τS = 12.0 ± 0.7 ms. Recently, Goodrow et al.10 analysed INa differences in ventricular and atrial human CMs, and in a commercially available hiPSC-CM line. These investigators observed that the activation V1/2 was about 5 mV more depolarized in hiPSC-CMs compared to native CMs, which is in line with our findings in Pluricyte® CMs. Overall, the differential results on hiPSC-CMs (including Pluricyte® CMs) vs. human adult native CMs could be explained, at least partly, by a differential expression of β-subunits in these cellular models, able to influence the channel voltage dependency and expression level.11 Furthermore, Veerman et al.12 showed that hiPSC-CMs express a considerable level of the neonatal isoform of Nav1.5, which decreases progressively with time of cell culture. The adult and neonatal isoforms differ in their voltage dependence,12 which could also account for differences between hiPSC-CMs and human adult native CMs. Our biophysical characterizations at the single-cell level, together with the MEA data in which the activation amplitude was robust, confirmed the functionality of Na+ channels in Pluricyte® CMs.
Repolarization in Pluricyte® CMs relied significantly on IKr, as expected.6 This is evident from our voltage-clamp recordings, in which IKr showed a large tail current, almost five times larger than the one reported by Magyar et al.13 in human native cells. This discrepancy may be explained by the methodological issues during native cardiomyocyte isolation, which could cause the loss of ion channels at the membrane. The rectifier ratio curve was useful in estimating the proportion of maximal IKr conductance functionally expressed during the AP plateau, thus contributing to APD. Considering that IKr recovery from inactivation is almost instantaneous at −40 mV, the rectifier ratio closely reflects the voltage dependence of channel steady-state inactivation.
The ICaL density measured in Pluricyte® CMs was larger than in human CMs,14 as already reported in other hiPSC-CM lines,5 and ICaL window was shifted towards more negative potentials, similar to what was shown by Ma et al.6 Notably, EADs occurred in a range of voltages compatible with the window ICaL measured, which is in line with a role of window ICaL in EAD generation in hiPSC-CMs.
The Ca2+-decay rate in Pluricyte® CMs was similar to that reported by Høydal et al.15 in human native CMs. In our experiments, the recordings of Ca2+-transients were performed at 0.4 Hz to allow complete relaxation, which was not achievable at faster frequencies. When we compared the inactivation kinetics of ICaL during the Ca2+-transient recordings, when the intracellular Ca2+ was minimally buffered, to those obtained in the voltage-clamp experiments with Ca2+ buffered by a high EGTA concentration, we observed a reduction in the τ from 51 ± 4.5 to 37 ± 12 ms, demonstrating the negative-feedback of SR Ca2+ release on ICaL (Ca2+-induced inactivation).
The response to caffeine was larger than in other hiPSC-CMs cell lines.16 The fractional SR Ca2+ release calculated for Pluricyte® CMs was 51%, in line with human native CMs (extrapolated from Coppini et al.14 and Høydal et al.,15 both approximatively 45–50%). In hiPSC-CMs, the T-tubular network, which promotes efficient Ca2+-induced Ca2+ release, lacks the abundance and detailed organization found in adult CMs. To measure the efficiency of coupling between ICaL and SR Ca2+ release, the ECC gain is widely used. Parikh et al.7 described a new protocol to induce the maturation of T-tubules in hiPSC-CMs and reported a lower ECC-gain value than Pluricyte® CMs (at 0 mV, ECC gain of the control hiPSC was 0.03 A.U., and for ‘tubulated’ cells 0.1 A.U., compared to Pluricyte® CMs of 0.15 A.U.). SERCA contribution to cytosolic Ca2+ clearance in Pluricyte® CMs was comparable with adult native CMs, as reported by Hwang et al.5 in rabbit isolated CMs and in different hiPSC-CMs lines (rabbit CM: 63%; hiPSC-CMs 58–63%). Taken together, the data suggest that the Ca2+ machinery of Pluricyte® CMs appears relatively similar to native CMs, and it assures a proper contraction (see Supplementary material online, Table S2 for a detailed comparison between electrophysiological and Ca2+-handling parameters of Pluricyte CMs, other hiPSC-CMs lines and human native CMs).
Drug-induced repolarization prolongation is an important component of proarrhythmic risk assessment. However, multiple literature reports indicate BVR as a better risk marker than prolongation alone.17 Sala et al.18 demonstrated increased repolarization variability in different hiPSC-CM lines upon the administration of the IKr blocker astemizole. We assessed the contribution of IKr to repolarization in Pluricyte® CMs at the AP level by applying dofetilide: this caused a pronounced AP prolongation and EAD generation in half of the cells treated. Furthermore, dofetilide (100 nmol/L) increased BVR significantly. Our data demonstrate that BVR can be used as a proarrhythmic marker in hiPSC-CMs, also when computed IK1 is injected through DC. Higher concentrations (than 100 nmol/L) of dofetilide in single Pluricyte® CMs had dramatic effects on repolarization, driving them to a non-reversible plateau arrest.
Interestingly, when we analysed the instability of repolarization in cells that developed EADs vs. those that did not, the increase in BVR from baseline to dofetilide was considerably larger in the +EAD cells. Temporal development of BVR preceded the first EAD, as was already demonstrated in native CMs,17 as well as in human embryonic stem cell-derived cardiomyocytes subjected to IKr block.19 This endorses the increase of BVR as a precursor of subsequent arrhythmias. BVR also increased (but less so) in cells that eventually did not develop EADs. Interestingly, BVR was significantly larger in cells with eventual EAD generation vs. those without, while APD did not show a statistically significant difference between the two groups. This endorses BVR as a more specific marker of arrhythmia inducibility compared to repolarization prolongation, which is especially relevant given the increasing use of hiPSC-CMs in the fields of safety pharmacology and drug development.
Multi-electrode arrays offer a medium/high throughput platform enabling the recording of extracellular field potentials, which have been correlated with action potentials and, to some extent, to the electrocardiogram, and of particular interest for (medicinal) compound testing.20 We focused on the effect of IKr block on FPD, its BVR and the arrhythmia inducibility. As already shown for isolated Pluricyte® CMs, BVR increase was concentration-dependent. At 3 nmol/L concentration of dofetilide, before the first arrhythmic event occurred, BVR had increased by >10 times, suggesting a mechanism similar to that in single hiPSC-CMs. Interestingly, when we analysed the presence of arrhythmia-like events from dofetilide 3 nmol/L to 10 nmol/L, we noticed a pronounced increase in the arrhythmia count (single abnormal impulses/bursts). Thus, also our MEA data suggest that an excessive increase in BVR precedes the first arrhythmic event under these conditions. Multi-electrode arrays have been included in the CiPA platform as one of the approaches to evaluate proarrhythmic risk of medicinal compound. We have now demonstrated that the dynamic changes in repolarization instability can be screened using BVR, e.g. using a medium-throughput technique.
Limitations
In this study, the injection of IK1 in Pluricyte CMs® through DC provided a resting membrane potential similar to those of native human CMs, assuring a proper recruitment of Na+ channels. At this moment, the combination of FP recording with IK1 injection is not available, so a direct comparison of results from single hiPSC-CMs and 2D monolayers cannot be made. However, electrotonic coupling of myocytes within the 2D monolayer, as well as electrophysiological maturation, may partly compensate for a difference in resting membrane potential between the two models.
A comparison between the duration of the action and field potentials revealed that mean FPD was significantly longer than APD (at baseline). This could be partially due to the fact that single Pluricyte® CMs were paced at 1 Hz, whereas the monolayers were spontaneously beating at approximately 0.5 Hz. Furthermore, the experimental conditions were different: in fact, the recording solutions (Tyrode solution and Pluricyte® CMs Medium) contained different concentrations of electrolytes. The injection of IK1 through DC, only possible at single-cell level, could contribute to the difference as well.
The differential concentration-dependent sensitivity of 2D monolayers and isolated Pluricyte® CMs to dofetilide can be attributed to multiple factors. Besides differences in experimental conditions between the two assays, electrotonic coupling and mechanical junctions in the 2D monolayers could promote electrophysiological maturation of hiPSC-CMs, thus potentially changing the expression, modulation and pharmacological responsiveness of ion channels (including IKr).
Conclusions
Pluricyte® CMs represent a valuable cellular model with ion-current characteristics and Ca2+-handling properties in various ways similar to human adult native CMs. This renders them suitable for in- vitro studies on transmembrane action potentials and field potentials. Repolarization instability upon IKr block, measured as beat-to-beat variability in both APD90 and FPD, is a useful parameter in the proarrhythmic risk assessment of agents with IKr-blocking effects. Increase in beat-to-beat variability of repolarization may outweigh APD90 prolongation per se as proarrhythmic parameter under these conditions.
Funding
This work was supported by the Netherlands CardioVascular Research Initiative (CVON2012-10 PREDICT) and the Health Foundation Limburg, Maastricht, The Netherlands (to P.G.A.V.).
Conflict of interest: T.d.K. and S.B. are, respectively, employee and co-founder of Ncardia. All other remaining authors have no conflicts of interest to declare.
Data availability
Data generated and analysed in this study are included in the article and supplementary material. There are no additional repositories. Data requests should be addressed to P.G.A.V.
Supplementary Material
References
- 1. van Mil A, Balk GM, Neef K, Buikema JW, Asselbergs FW, Wu SM. et al. Modelling inherited cardiac disease using human induced pluripotent stem cell-derived cardiomyocytes: progress, pitfalls, and potential. Cardiovasc Res 2018;114:1828–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Bowes J, Brown AJ, Hamon J, Jarolimek W, Sridhar A, Waldron G. et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov 2012;11:909–22. [DOI] [PubMed] [Google Scholar]
- 3. Shih HP, Zhang X, Aronov AM.. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nat Rev Drug Discov 2018;17:19–33. [DOI] [PubMed] [Google Scholar]
- 4. Blinova K, Dang Q, Millard D, Smith G, Pierson J, Guo L. et al. International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment. Cell Rep 2018;24:3582–92. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Hwang HS, Kryshtal DO, Feaster TK, Sánchez-Freire V, Zhang J, Kamp TJ. et al. Comparable calcium handling of human iPSC-derived cardiomyocytes generated by multiple laboratories. J Mol Cell Cardiol 2015;85:79–88. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Ma J, Guo L, Fiene SJ, Anson BD, Ja T, Kamp TJ. et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol 2011;301:2006–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Parikh SS, Blackwell DJ, Gomez-Hurtado N, Frisk M, Wang L, Kim K. et al. Thyroid and glucocorticoid hormones promote functional t-tubule development in human-induced pluripotent stem cell-derived cardiomyocytes. Circ Res 2017;121:1323–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Verkerk AO, Veerman CC, Zegers JG, Mengarelli I, Bezzina CR, Wilders R.. Patch-clamp recording from human induced pluripotent stem cell-derived cardiomyocytes: improving action potential characteristics through dynamic clamp. IJMS 2017;18:1873. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Sakakibara Y, Furukawa T, Singer DH, Jia H, Backer CL, Arentzen CE. et al. Sodium current in isolated human ventricular myocytes. Am J Physiol 1993;265:H1301–9. [DOI] [PubMed] [Google Scholar]
- 10. Goodrow RJ Jr, Desai S, Treat JA, Panama BK, Desai M, Nesterenko VV. et al. Biophysical comparison of sodium currents in native cardiac myocytes and human induced pluripotent stem cell-derived cardiomyocytes. J Pharmacol Toxicol Methods 2018;90:19–30. [DOI] [PubMed] [Google Scholar]
- 11. Moreau A, Mercier A, Thériault O, Boutjdir M, Burger B, Keller DI. et al. Biophysical, molecular, and pharmacological characterization of voltage-dependent sodium channels from induced pluripotent stem cell-derived cardiomyocytes. Can J Cardiol 2017;33:269–78. [DOI] [PubMed] [Google Scholar]
- 12. Veerman CC, Mengarelli I, Lodder EM, Kosmidis G, Bellin M, Zhang M. et al. Switch from fetal to adult SCN5A isoform in human induced pluripotent stem cell-derived cardiomyocytes unmasks the cellular phenotype of a conduction disease-causing mutation. J Am Heart Assoc 2017;6:e005135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Magyar J, Iost N, Kortvely A, Banyasz T, Virag L, Szigligeti P. et al. Effects of endothelin-1 on calcium and potassium currents in undiseased human ventricular myocytes. Pflügers Arch 2000;441:144–9. [DOI] [PubMed] [Google Scholar]
- 14. Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F. et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 2013;127:575–84. [DOI] [PubMed] [Google Scholar]
- 15. Hoydal MA, Kirkeby-Garstad I, Karevold A, Wiseth R, Haaverstad R, Wahba A. et al. Human cardiomyocyte calcium handling and transverse tubules in mid-stage of post-myocardial-infarction heart failure. ESC Heart Fail 2018;5:332–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Zhang XH, Haviland S, Wei H, Saric T, Fatima A, Hescheler J. et al. Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects. Cell Calcium 2013;54:57–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, van Opstal J. et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 2004;110:2453–9. [DOI] [PubMed] [Google Scholar]
- 18. Sala L, Yu Z, Ward-van Oostwaard D, van Veldhoven JP, Moretti A, Laugwitz KL. et al. A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells. EMBO Mol Med 2016;8:1065–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Nalos L, Varkevisser R, Jonsson MK, Houtman MJ, Beekman JD, van der Nagel R. et al. Comparison of the ikr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes. Br J Pharmacol 2012;165:467–78. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Kim J, Shah D, Potapov I, Latukka J, Aalto-Setälä K, Räsänen E.. Scaling and correlation properties of RR and QT intervals at the cellular level. Sci Rep 2019;9:3651. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Data generated and analysed in this study are included in the article and supplementary material. There are no additional repositories. Data requests should be addressed to P.G.A.V.